Bifidobacterium longum spp. infantis 35624, originally isolated from the ileal mucosa of an individual free of gastrointestinal disease has been shown to survive transit through the gastrointestinal tract and to exert potent antiinflammatory effects in vivo in animal models. Other homeostatic effects, such as an enhancement of gut barrier function have also been demonstrated and of relevance to potential clinical indication, this organism has also been shown to accelerate intestinal transit and diminish visceral hypersensitivity. Not surprisingly, therefore clinical trials have focused on irritable bowel syndrome where consistent and clinically meaningful benefits have been demonstrated.

Original languageEnglish (US)
Title of host publicationThe Microbiota in Gastrointestinal Pathophysiology
Subtitle of host publicationImplications for Human Health, Prebiotics, Probiotics, and Dysbiosis
Number of pages2
ISBN (Electronic)9780128040621
ISBN (Print)9780128040249
StatePublished - Jan 1 2017


  • Antiinflammatory
  • Bifidobacterium longum spp. infantis 35624
  • Dendritic cells
  • Diverticulitis
  • Interleukin 10
  • Irritable bowel syndrome
  • Regulatory T-cell response
  • Visceral hypersensitivity

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Bifidobacterium longum spp. infantis'. Together they form a unique fingerprint.

Cite this